These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 30544111)

  • 21. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
    Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.
    Schroeder-Castagno M; Del Rio-Serrato A; Wilhelm A; Romero-Suárez S; Schindler P; Alvarez-González C; Duchow AS; Bellmann-Strobl J; Ruprecht K; Hastermann M; Grütz G; Wildemann B; Jarius S; Schmitz-Hübsch T; Paul F; Infante-Duarte C
    J Neuroinflammation; 2022 Oct; 19(1):239. PubMed ID: 36183103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
    Lin L; Wu Y; Hang H; Lu J; Ding Y
    Front Immunol; 2022; 13():853891. PubMed ID: 35898513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
    Carta S; Dinoto A; Capobianco M; Valentino P; Montarolo F; Sala A; Reindl M; Lo Re M; Chiodega V; Branger P; Audoin B; Aboab J; Papeix C; Collongues N; Kerschen P; Zephir H; Créange A; Bourre B; Schanda K; Flanagan EP; Redenbaugh V; Villacieros-Álvarez J; Arrambide G; Cobo-Calvo A; Ferrari S; Marignier R; Mariotto S
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):e200188. PubMed ID: 38134369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
    Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
    Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
    Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
    PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?
    Chu F; Shi M; Liu C; Zhu J
    Clin Exp Immunol; 2023 Oct; 213(3):363-370. PubMed ID: 37161978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-33 as a Biomarker Affecting Intrathecal Synthesis of Immunoglobulin in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Wang M; Xia D; Sun L; Bi J; Xie K; Wang P
    Eur Neurol; 2023; 86(4):256-262. PubMed ID: 37100033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different roles of soluble CD40 ligand in central nervous system damage.
    Du L; Chang H; Wei Y; Zhang X; Yin L
    Neurol Res; 2020 May; 42(5):372-378. PubMed ID: 32178599
    [No Abstract]   [Full Text] [Related]  

  • 32. Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity.
    Song Y; Zhu M; Liu C; Zheng C; Zhou Y; Zhu J; Jin T
    Immunobiology; 2019 May; 224(3):397-401. PubMed ID: 30852049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders.
    Monteiro C; Fernandes G; Kasahara TM; Barros PO; Dias ASO; Araújo ACRA; Ornelas AMM; Aguiar RS; Alvarenga R; Bento CAM
    J Neuroimmunol; 2019 May; 330():12-18. PubMed ID: 30769212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
    Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
    Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.
    Kaneko K; Kuroda H; Matsumoto Y; Sakamoto N; Yamazaki N; Yamamoto N; Umezawa S; Namatame C; Ono H; Takai Y; Takahashi T; Fujimori J; Nakashima I; Harigaya Y; Lassmann H; Fujihara K; Misu T; Aoki M
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200293. PubMed ID: 39133885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
    You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
    Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance.
    Jarius S; Franciotta D; Paul F; Ruprecht K; Bergamaschi R; Rommer PS; Reuss R; Probst C; Kristoferitsch W; Wandinger KP; Wildemann B
    J Neuroinflammation; 2010 Sep; 7():52. PubMed ID: 20825655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG
    Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
    Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
    J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks.
    Uzawa A; Mori M; Sawai S; Masuda S; Muto M; Uchida T; Ito S; Nomura F; Kuwabara S
    Clin Chim Acta; 2013 Jun; 421():181-3. PubMed ID: 23535508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.